Qualigen Therapeutics Inc (QLGN) — Cash Flow-to-Debt Ratio
Qualigen Therapeutics Inc (QLGN) has a Cash Flow-to-Debt Ratio of -0.43x as of September 2025, meaning its operating cash flow of $-2.14 Million could theoretically repay 0% of its total liabilities ($4.92 Million) in one year. See Qualigen Therapeutics Inc free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Qualigen Therapeutics Inc Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for Qualigen Therapeutics Inc across 13 annual periods. Also explore net asset growth rate of Qualigen Therapeutics Inc to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Qualigen Therapeutics Inc (2012–2024)
Year-by-year debt coverage analysis for Qualigen Therapeutics Inc. For market capitalisation and broader financial context, see Qualigen Therapeutics Inc stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -3.15x | $-6.33 Million | $2.01 Million | ▼ -26.5% |
| 2023 | -2.49x | $-10.30 Million | $4.14 Million | ▼ -94.0% |
| 2022 | -1.28x | $-13.25 Million | $10.32 Million | ▲ +45.3% |
| 2021 | -2.35x | $-14.73 Million | $6.27 Million | ▼ -160.8% |
| 2020 | -0.90x | $-9.76 Million | $10.83 Million | ▼ -2765.8% |
| 2019 | 0.03x | $57.33K | $1.70 Million | ▲ +101.5% |
| 2018 | -2.25x | $-13.33 Million | $5.93 Million | ▲ +17.8% |
| 2017 | -2.73x | $-7.40 Million | $2.71 Million | ▲ +43.7% |
| 2016 | -4.85x | $-15.21 Million | $3.13 Million | ▼ -14.9% |
| 2015 | -4.22x | $-5.72 Million | $1.35 Million | ▼ -357.9% |
| 2014 | -0.92x | $-1.16 Million | $1.25 Million | ▲ +57.7% |
| 2013 | -2.18x | $-1.96 Million | $897.96K | ▲ +35.5% |
| 2012 | -3.38x | $-3.08 Million | $910.48K | — |